Auger electrons for cancer therapy–a review

A Ku, VJ Facca, Z Cai, RM Reilly - EJNMMI radiopharmacy and chemistry, 2019 - Springer
Abstract Background Auger electrons (AEs) are very low energy electrons that are emitted
by radionuclides that decay by electron capture (eg 111 In, 67 Ga, 99m Tc, 195m Pt, 125 I …

Strategies for the nuclear delivery of metal complexes to cancer cells

M Huynh, R Vinck, B Gibert, G Gasser - Advanced Materials, 2024 - Wiley Online Library
The nucleus is an essential organelle for the function of cells. It holds most of the genetic
material and plays a crucial role in the regulation of cell growth and proliferation. Since …

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

C Müller, CA Umbricht, N Gracheva, VJ Tschan… - European journal of …, 2019 - Springer
Purpose The prostate-specific membrane antigen (PSMA) has emerged as an interesting
target for radionuclide therapy of metastasized castration-resistant prostate cancer …

Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons

S Aghevlian, AJ Boyle, RM Reilly - Advanced drug delivery reviews, 2017 - Elsevier
Radioimmunotherapy (RIT) aims to selectively deliver radionuclides emitting α-particles, β-
particles or Auger electrons to tumors by conjugation to monoclonal antibodies (mAbs) that …

Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine

RM Reilly - Journal of Nuclear Medicine, 2007 - Soc Nuclear Med
Targeting of tumors with radionuclides for radiotherapeutic purposes is often limited by
inadequate delivery to lesions using currently available targeting vehicles (eg, monoclonal …

Subcellular targeting of theranostic radionuclides

BM Bavelaar, BQ Lee, MR Gill, N Falzone… - Frontiers in …, 2018 - frontiersin.org
The last decade has seen rapid growth in the use of theranostic radionuclides for the
treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging rely …

[Lys40 (Ahx-DTPA-111In) NH2] exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting

D Wild, M Béhé, A Wicki, D Storch… - Journal of Nuclear …, 2006 - Soc Nuclear Med
High levels of glucagon-like peptide-1 (GLP-1) receptor expression in human insulinomas
and gastrinomas provide an attractive target for imaging, therapy, and intraoperative tumor …

111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified …

DL Costantini, C Chan, Z Cai, KA Vallis… - Journal of Nuclear …, 2007 - Soc Nuclear Med
The cytotoxicity and tumor-targeting properties of the anti-HER2/neu monoclonal antibody
trastuzumab modified with peptides (CGYG PKKKRKV GG) harboring the nuclear …

Targeting the nucleus: an overview of Auger-electron radionuclide therapy

B Cornelissen, KA Vallis - Current drug discovery technologies, 2010 - ingentaconnect.com
The review presented here lays out the present state of the art in the field of radionuclide
therapies specifically targeted against the nucleus of cancer cells, focussing on the use of …

Auger processes in the 21st century

RW Howell - International journal of radiation biology, 2008 - Taylor & Francis
Purpose: The extreme radiotoxicity of Auger electrons and their exquisite capacity to
irradiate specific molecular sites has prompted scientists to extensively investigate their …